Clinical Trial Update: Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma [Phase 2]

View source ↗

Summary

A Phase 2 single-dose crossover trial assessing the early bronchodilating effect of FlutiForm HFA pMDI in adults with mild to moderate asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FlutiForm HFA pMDI (fluticasone/formoterol)

Snippet

Sponsor: SkyePharma AG | Conditions: Mild to Moderate Asthma | Phase 2 | Status: COMPLETED